These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35699128)

  • 1. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
    Ding Y; Qian J; Zhang S; Xu D; Leng X; Zhao J; Wang Q; Zhang W; Tian X; Li M; Zeng X
    Int J Rheum Dis; 2022 Sep; 25(9):982-990. PubMed ID: 35699128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
    Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
    Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
    Cansu DÜ; Korkmaz C
    Clin Rheumatol; 2023 Oct; 42(10):2601-2610. PubMed ID: 36396789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension using a Japanese claims database.
    Tokushige N; Hayashi Y; Omura J; Jinnai T; Atsumi T
    Mod Rheumatol; 2024 Oct; 34(6):1202-1212. PubMed ID: 38581672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension.
    Kularatne M; Boucly A; Savale L; Solinas S; Cheron C; Roche A; Jevnikar M; Jaïs X; Montani D; Humbert M; Sitbon O
    Expert Opin Pharmacother; 2023; 24(18):2101-2115. PubMed ID: 37869785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
    Yasuoka H; Shirai Y; Tamura Y; Takeuchi T; Kuwana M
    Circ J; 2018 Jan; 82(2):546-554. PubMed ID: 28904255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data.
    Thoreau B; Mouthon L
    Autoimmun Rev; 2024 Apr; 23(4):103506. PubMed ID: 38135175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.
    Zhao J; Wang Q; Deng X; Qian J; Tian Z; Liu Y; Li M; Zeng X
    Pharmacol Ther; 2022 Nov; 239():108192. PubMed ID: 35461923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review.
    Kato M; Kataoka H; Odani T; Fujieda Y; Otomo K; Oku K; Horita T; Yasuda S; Atsumi T; Ohira H; Tsujino I; Nishimura M; Koike T
    Lupus; 2011 Oct; 20(10):1047-56. PubMed ID: 21676917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immune cells in the pathogenesis of connective tissue diseases-associated pulmonary arterial hypertension.
    Li Z; Ma J; Wang X; Zhu L; Gan Y; Dai B
    Front Immunol; 2024; 15():1464762. PubMed ID: 39355239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
    Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
    Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis.
    Lewis C; Sanderson R; Vasilottos N; Zheutlin A; Visovatti S
    Heart Fail Clin; 2023 Jan; 19(1):45-54. PubMed ID: 36435572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
    Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
    Jais X; Launay D; Yaici A; Le Pavec J; Tchérakian C; Sitbon O; Simonneau G; Humbert M
    Arthritis Rheum; 2008 Feb; 58(2):521-31. PubMed ID: 18240255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary hypertension in connective tissue diseases: What every CTD specialist should know - but is afraid to ask!
    Sanges S; Sobanski V; Lamblin N; Hachulla E; Savale L; Montani D; Launay D
    Rev Med Interne; 2024 Jan; 45(1):26-40. PubMed ID: 37925256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.
    Condliffe R; Kiely DG; Peacock AJ; Corris PA; Gibbs JS; Vrapi F; Das C; Elliot CA; Johnson M; DeSoyza J; Torpy C; Goldsmith K; Hodgkins D; Hughes RJ; Pepke-Zaba J; Coghlan JG
    Am J Respir Crit Care Med; 2009 Jan; 179(2):151-7. PubMed ID: 18931333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.
    Zanatta E; Polito P; Famoso G; Larosa M; De Zorzi E; Scarpieri E; Cozzi F; Doria A
    Exp Biol Med (Maywood); 2019 Feb; 244(2):120-131. PubMed ID: 30669861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension in connective tissue diseases: an update.
    Aithala R; Alex AG; Danda D
    Int J Rheum Dis; 2017 Jan; 20(1):5-24. PubMed ID: 28205373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus-associated pulmonary arterial hypertension.
    Sanges S; Savale L; Lamblin N; Rémy-Jardin M; Humbert M; Sobanski V
    ESC Heart Fail; 2019 Dec; 6(6):1322-1325. PubMed ID: 31536678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.